Frans Serpa

Frans Serpa

Auto-generated profile, based on publicly available information

Frans Serpa

Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2024 in Heart Rhythm
Verified
Journal Article
Closed access
FSFrans Serpa
Frans Serpa
ARAndré Rivera
André Rivera
JFJulia M. Fernandes
Julia M. Fernandes
MBMarcelo Antonio Pinheiro Braga
Marcelo Antonio Pinheiro Braga
BABeatriz Araújo
Beatriz Araújo
DKDaniel B. Kramer
Daniel B. Kramer

25 April 2024 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
ARAndré Rivera
André Rivera
DGDouglas Mesadri Gewehr
Douglas Mesadri Gewehr
MBMarcelo A. P. Braga
Marcelo A. P. Braga
PCPedro E. P. Carvalho
Pedro E. P. Carvalho
CTCaique M. P. Ternes
Caique M. P. Ternes
ADAndre D’Avila
Andre D’Avila

1 September 2025 in EP Europace
Verified
Journal Article
Open access
BABeatriz Araújo
Beatriz Araújo
ARAndré Rivera
André Rivera
VTVanessa de Oliveira Tapioca
Vanessa de Oliveira Tapioca
LBLucas M Barbosa
Lucas M Barbosa
LCLucas Caetano
Lucas Caetano
ANAndrea Natale
Andrea Natale
Aims: Catheter ablation is the standard treatment for symptomatic atrial fibrillation (AF) and can be performed under general anaesthesia (GA) or varying levels of sedation to optimize patient comfort and lesion formation. However, the effect of different anaesthesia strategies on AF recurrence rates remains uncertain. Methods and results: We systematically searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for randomized controlled trials (RCTs) and observational studies comparing outcomes of catheter ablation under GA vs. sedation (including deep, moderate, and conscious sedation). We pooled risk ratios (RR) with 95% confidence intervals (CI) with a random effects model. R version 4.4.1 was used for statistical analyses. Our systematic review and meta-analysis included 6 RCTs and 17 observational studies, corresponding to 12 302 patients assigned to either sedation (n = 8952) or GA (n = 3350). There was no difference in recurrence of atrial tachyarrhythmias (ATAs) between groups (RR 1.15; 95% CI 0.97–1.36; P = 0.10; 95% prediction interval 0.66–2.01). There was no significant subgroup interaction in the recurrence of AF according to sedation type (conscious vs. mild vs. moderate sedation vs. deep sedation) (P = 0.20) or AF type (persistent AF vs. non-persistent) (P = 0.20). Conclusion: In patients undergoing catheter ablation for AF, there was no significant difference in recurrence of ATA between GA and sedation.

10 October 2024 in Current Problems in Cardiology
Verified
Journal Article
Closed access
JFJulia M. Fernandes
Julia M. Fernandes
RPRafael P.S. Pinheiro
Rafael P.S. Pinheiro
FSFrans Serpa
Frans Serpa
NANaieli M. de Andrade
Naieli M. de Andrade
VPVinicius Pereira
Vinicius Pereira
WGWilton F. Gomes
Wilton F. Gomes

21 October 2024 in Heart Rhythm O2
Verified
Journal Article
Open access
FSFrans Serpa
Frans Serpa
ATArchana Tale
Archana Tale
PZPeter J. Zimetbaum
Peter J. Zimetbaum
DKDaniel B. Kramer
Daniel B. Kramer
Atrial fibrillation (AF) is associated with increased health care costs; however, comprehensive data on the financial burden of AF remain limited. The purpose of this study was to delineate health care expenditures among patients with AF. We used the longitudinal panels from the Medical Expenditure Panel Survey covering 2016–2019 to estimate health care expenditures associated with AF. We identified individuals 18 years and older with AF in the first year of each panel (2016–2018) by using the International Classification of Disease, Tenth Revision codes. Covariates included sociodemographic characteristics and comorbidities. Health care expenditures were derived from the second year of each panel (2017–2019) to reflect the cost of having the condition for an entire year. Adjusted mean annual costs were calculated, including total health care expenditure, hospital inpatient, emergency department visits, office-based visits, outpatient visits, home health visits, prescribed medicines, and other expenses. Adjusted models were used to estimate the mean annual incremental total health care cost associated with AF. The weighted study population included 3,080,055 adults with AF (382 respondents; mean age 71.5; 89.9% white). The adjusted annual total health care cost in adults with AF totaled $14,083 (95% confidence interval $10,887–$17,279) compared with $8771 (95% confidence interval $8106–$9436) for those without AF. The primary drivers of cost over time were hospital inpatient care, office-based visits, and prescribed medications. The annual incremental total health care cost associated with AF was $5312 per adult (in 2019 U.S. dollars). Adults with AF in the United States face a higher financial burden across various health care services than do those without the condition, with consistently increasing expenses in inpatient care and prescribed medicines. Further research is needed to identify the independent contribution of AF to these costs.

19 June 2024 in Heart Failure Reviews
Verified
Journal Article
Closed access
PDF file
FSFrans Serpa
Frans Serpa
CFCaitlin M. Finn
Caitlin M. Finn
UTUsman A. Tahir
Usman A. Tahir